Scientists in South Korea engineered a new cancer-targeting, TCR-like antibody that binds the PRAME complex, aiming to extend immunotherapy to patients who have lacked effective options. The laboratory validation was published in Cancer Immunology, Immunotherapy. The approach targets PRAME, a cancer antigen complex intended to improve selectivity of immune activation toward tumor cells while engaging immune effector mechanisms. The report details preclinical confirmation of binding and functional activity, positioning the antibody for further translational work. The program highlights how developers are continuing to diversify targets beyond classical tumor antigens, using PRAME complex recognition to build next-generation immunotherapy candidates.